Eric Ruby Joins Presidio Pharmaceuticals, Inc. as Vice President of Regulatory Affairs

Eric Ruby Joins Presidio Pharmaceuticals, Inc. as Vice President of Regulatory Affairs  
SAN FRANCISCO - (Business Wire) Presidio Pharmaceuticals, Inc. is pleased to announce that Eric Ruby has joined the Company as Vice President of Regulatory Affairs.

"The addition of Eric to our team significantly contributes to Presidio's clinical development of our NS5A inhibitor in 2010," said Omar Haffar, Founder, President and Chief Executive Officer. "Eric's extensive background in regulatory affairs will enhance and complement Presidio's existing management team and strengthen our ability to create value for the company and our investors. All of us at Presidio look forward to working with Eric and to maintaining our pace of building a vibrant drug development organization."

Eric provides more than twenty years of experience in regulatory strategy, data review, and communications with regulatory agencies. He served previously as Senior Director, Regulatory Affairs at Alnylam Pharmaceuticals, where he was responsible for regulatory filings to support clinical trials in the U.S. and Europe. Prior to Alnylam, Eric led regulatory communications and filings at Vertex Pharmaceuticals for HCV drug telaprevir from the initial clinical trial through Phase 2b. During his career, Eric has led or supervised regulatory strategy and agency interactions to support clinical studies for 15 compounds. Prior to his career in industry, Eric held positions with the Food and Drug Administration for 8 years, first as a chemistry reviewer, and subsequently as a manager for drug metabolism and pharmacokinetic studies.

Eric earned his B.A. degree in Chemistry at Harvard University, and an M.S. degree in Organic Chemistry at the University of California, Berkeley.

"I am very pleased to join Presidio Pharmaceuticals," said Mr. Ruby. "The team at Presidio has impressive experience in antiviral drug discovery and development and has the potential to make a significant contribution to the treatment of hepatitis C. I look forward to building the company's regulatory function and working with the team to move compounds rapidly through clinical development."


Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HIV-1 and HCV. For more information, please visit our website at

 Presidio Pharmaceuticals, Inc.
Omar K. Haffar, PhD, 415-655-7561
[email protected] 


Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.